TargetBeta
HLA-B
major histocompatibility complex, class I, B · also AS · Histocompatibility complex
1 program in company-led studies act on HLA-B, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Akt-1 Antisense Oligonucleotide WGI-0301rule | Zhejiang Haichang Biotech | phase 2 | 44 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Renal Cell, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Akt-1 Antisense Oligonucleotide WGI-0301 · Zhejiang Haichang Biotech · phase 2 · NCT06309485
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.